Antineoplastic Combinations
Kisqali Femara Co-Pack (letrozole/ribociclib)
KISQALI® (ribociclib) is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Manufacturer's Website: Kisqali Average retail cost: $2,800/month
Decitabine/cedazuridine, sold under the brand name Inqovi, is a fixed-dosed combination medication for the treatment of adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor... Wikipedia
Manufacturer's Website: Inqovi Average retail cost: $7,850/month
Lonsurf (tipiracil/trifluridine)
Trifluridine/tipiracil (trade name Lonsurf) is a combination drug for the treatment of metastatic colorectal cancer. It is a combination of two active pharmaceutical ingredients: trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor. Tipiracil prevents rapid metabolism of trifluridine, increasing the bioavailability of trifluridine...Wikipedia
Manufacturer's Website: Lonsurf Average retail cost: $12,150/month
Vyxeos (cytarabine liposomal/daunorubicin liposomal)
VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Manufacturer's Website: Vyxeos Average retail cost: *
* This prescription is provided by your healthcare provider. It cannot be filled in a pharmacy and may be expensive.
™
Copyright 2006-2023 Automated Clinical Guidelines, LLC. All rights reserved.
™
Home Contact FAQ
Account